title: [Dysarthria during irinotecan administration].
authors.forename: B
authors.initials: B
authors.lastname: Ceccaldi
authors.forename: F
authors.initials: F
authors.lastname: Kara
authors.forename: H
authors.initials: H
authors.lastname: Mommeja-Marin
authors.forename: M
authors.initials: M
authors.lastname: Bègue
authors.forename: P
authors.initials: P
authors.lastname: Saint Blancard
authors.forename: E
authors.initials: E
authors.lastname: Le Marec
authors.forename: D
authors.initials: D
authors.lastname: Hauteville
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004401:Dysarthria / Q000139:chemically induced* / Q000175:diagnosis; D016889:Endometrial Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008279:Magnetic Resonance Imaging
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin